85 results on '"Cool M"'
Search Results
2. A survey among Flemish gastroenterologists about endoscopic sedation practices in colorectal cancer screening.
- Author
-
Arnaert, S., Vandebroek, V., Persyn, D., Cool, M., Lambrecht, G., Desmet, G., and Deboever, G.
- Published
- 2023
- Full Text
- View/download PDF
3. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C‐infected patients treated with direct‐acting antivirals with and without pegylated interferon: A Belgian experience
- Author
-
Bielen, R., Moreno, C., Van Vlierberghe, H., Bourgeois, S., Mulkay, J.‐P., Vanwolleghem, T., Verlinden, W., Brixco, C., Decaestecker, J., de Galocsy, C., Janssens, F., Van Overbeke, L., Van Steenkiste, C., DʼHeygere, F., Cool, M., Wuyckens, K., Nevens, F., and Robaeys, G.
- Published
- 2017
- Full Text
- View/download PDF
4. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium : an observational study
- Author
-
Bourgeois, S, primary, Mulkay, JP, additional, Cool, M, additional, Verhelst, X, additional, Robaeys, G, additional, Lasser, L, additional, Lefebvre, V, additional, Colle, I, additional, Van Steenkiste, C, additional, Decaestecker, J, additional, Coulon, S, additional, Venken, K, additional, and Vanwolleghem, T, additional
- Published
- 2021
- Full Text
- View/download PDF
5. THE OOPS STUDY: THE OOSTENDE POLYP SIZING STUDY
- Author
-
Guy Lambrecht, A Billiet, Cool M, Guido Deboever, SV Langendonck, and K Hertveldt
- Subjects
Computer science ,Sizing ,Marine engineering - Published
- 2020
6. Value of carbon dioxide wedged venography and transvenous liver biopsy in the definitive diagnosis of Abernethy malformation
- Author
-
Collard, B., Maleux, G., Heye, S., Cool, M., Bielen, D., George, C., Roskams, T., and Van Steenbergen, W.
- Published
- 2006
- Full Text
- View/download PDF
7. THE OOPS STUDY: THE OOSTENDE POLYP SIZING STUDY
- Author
-
Langendonck, SV, additional, Billiet, A, additional, Hertveldt, K, additional, Cool, M, additional, Lambrecht, G, additional, and Deboever, G, additional
- Published
- 2020
- Full Text
- View/download PDF
8. A novel mouse model of HIV-1 disease
- Author
-
Jolicoeur, P, Kay, DG, Cool, M, Jothy, S, Rebai, N, and Hanna, Z
- Published
- 1999
- Full Text
- View/download PDF
9. Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort
- Author
-
GUARD C, Study Group, Hassanein, T, Bakalos, G, Ahlers, S, Shiffman, Ml, Tallarico, L, Reddy, Kr, Orlandini, A, Ferenci, P, Derbala, M, Coppola, C, Foster, Gr, Basho, J, Shabanaj, G, Harxhi, A, Debzi, N, Afredj, N, Guessab, N, Mahindad, N, Mahiou, H, Aissaoui, M, Al Qameesh, J, Al Ghandoor, Z, Assene, C, Bastens, B, Brixko, C, Cool, M, De Galocsy, C, Delwaide, J, George, C, Laukens, P, Lefebvre, V, Mulkay, Jp, Nevens, F, Servais, B, Van Vlierberghe, H, Horsmans, Y, Henrion, J, Sprengers, D, Michielsen, P, Bourgeois, S, Lasser, L, Langlet, P, Robaeys, G, Martinet, Jp, Warzee, P, Hoste, P, Reynaert, H, Juriens, I, Decaestecker, J, Van Der Meersch, F, Janssens, F, Ahmetagic, S, Verhaz, A, Bevanda, M, Calkic, L, Ibrahimpasic, N, Mesihovic, R, Mello, Ce, Ruiz, Fj, Martins Junior, E, Ferraz, Ml, Silva, G, Mendes, C, Lyra, A, Silva, Mh, Gomide, G, Fernandes, Jc, Pereira, P, Correa, Mc, Teixeira, R, Yousry, A, Hanno, A, Gabr, M, Omar, A, Esmat, G, Karatapanis, S, Nikolopoulou, V, Giannoulis, G, Manolakopoulos, S, Elefsiniotis, I, Drakoulis, C, Dimitroulopoulos, D, Kanatakis, S, Ketikoglou, I, Mimidis, K, Evgenidis, N, Akriviades, E, Vafiadi Zoubouli, I, Tsianos, E, Mela, M, Orfanou, E, Mousoulis, G, Karagiannis, I, Manesis, E, Varga, M, Nemesánszky, E, Fried, K, Schuller, J, Szalay, F, Lengyel, G, Tornai, I, Banyai, T, Lesch, M, Nagy, I, Gervain, J, Tusnadi, A, Schneider, F, Szentgyörgyi, L, Hunyady, B, Vincze, A, Tolvaj, G, Varkonyi, I, Makkai, E, Enyedi, J, Racz, I, Hausinger, P, Váczi, Z, Patai, Á, Ozsvár, Z, Lakner, L, Ribiczey, P, Bhalla, A, Somani, S, Luaia, R, Rao, P, Philip, M, Lawate, P, Nagral, A, Sood, A, Parikh, S, Merat, S, Nassiri Toosi, M, Alavian, Sm, Zali, Mr, Daryani, Ne, Drenaggi, D, Attili, Af, Bandiera, F, Bassi, P, Bellati, G, Bellantani, S, Brunetto, MAURIZIA ROSSANA, Bruno, S, Castelli, F, Castellacci, R, Cattelan, Am, Colombo, M, Craxi, A, D'Angelo, S, Colombo, S, Demelia, L, Di Perri, G, Di Giacomo, A, Ferrari, C, Francisci, D, Casinelli, K, Ganga, R, Costa, C, Mangia, A, Russo, Fp, Matarazzo, F, Mazzella, G, Mazzeo, M, Memoli, M, Montalbano, M, Montalto, G, Pieri, A, Passariello, N, Picciotto, A, Pietrangelo, A, Pirisi, M, Quirino, T, Raimondo, G, Rapaccini, Gl, Rizzardini, G, Rizzetto, M, Russello, M, Sabusco, G, Santantonio, T, Soardo, G, Amedea, A, Verucchi, G, Vinelli, F, Zignego, Al, Zuin, M, Ascione, A, Vinci, M, Pigozzi, Mg, Tundo, P, Saracco, Gm, Amoroso, P, Andreoni, M, Colletta, C, Erne, E, Megna, As, Biglino, A, Chiriaco, P, Foti, G, Spinzi, G, D'Amico, E, Paik, Sw, Ahn, Sh, Lee, Yn, Kim, Y, Yang, J, Han, Sy, Varghese, R, Al Gharabally, A, Askar, H, Sharara, A, Yaghi, C, Rached, Aa, Houmani, Z, Zaarour, F, Dohaibi, A, Ivanovski, L, Joksimovic, N, Abbas, Z, Memon, S, Mohsin, A, Masood, S, Hashmi, Z, Halota, W, Deron, Z, Mazur, W, Flisiak, R, Lipczynski, A, Musialik, J, Piekarska, A, Augustyniak, K, Baka Cwierz, B, Simon, K, Gietka, A, Berak, H, Sieklucki, J, Radowska, D, Szlauer, B, Piekos, T, Olszok, I, Jablkowski, M, Orszulak, G, Warakomska, I, Aleixo, Mj, Valente, C, Macedo, G, Sarmento Castro, R, Roxo, F, Faria, T, Mansinho, K, Velez, J, Ramos, Jp, Guerreiro, H, Alberto, S, Monteverde, C, Serejo, F, Peixe, P, Malhado, J, Curescu, M, Streinu Cercel, A, Caruntu, F, Livia, H, Preotescu, L, Arama, V, Ancuta, I, Gheorghe, L, Stanciu, C, Trifan, A, Acalovschi, M, Andreica, V, Pascu, O, Lencu, M, Sporea, I, Olteanu, D, Ionita Radu, F, Fierbinteanu Braticevici, C, Motoc, A, Silaghi, R, Musat, M, Coman, F, Stan, M, Cijevschi, C, Miftode, E, Delic, D, Jesic, R, Nozic, D, Svorcan, P, Fabri, M, Konstantinovic, L, Pelemis, M, Jankovic, G, Todorovic, Z, Nagorni, A, Kupcova, V, Skladany, L, Szantova, M, Krkoska, D, Jarcuska, P, Schreter, I, Oltman, M, Bocakova, J, Bunganic, I, Holoman, J, Giguere, A, Abdou, A. M., Basic (bio-) Medical Sciences, Gastroenterology, Laboratory of Molecullar and Cellular Therapy, Liver Cell Biology, Michielsen, Peter, GUARD-C Study Group, Graham R. Foster, Carmine Coppola, Moutaz Derbala, Peter Ferenci, Alessandra Orlandini, K. Rajender Reddy, Ludovico Tallarico, Mitchell L. Shiffman, Silke Ahler, Georgios Bakalo, Tarek Hassanein, GUARD-C Study Group: [.., Davide Drenaggi, Adolfo Francesco Attili, Franco Bandiera, Paolo Bassi, Giorgio Bellati, Stefano Bellantani, Maurizia Brunetto, Savino Bruno, Francesco Castelli, Roberto Castellacci, Anna Maria Cattelan, Massimo Colombo, Antonio Craxi, Salvatore D'angelo, Silvia Colombo, Luigi Demelia, Giovanni Di Perri, Antonio Di Giacomo, Carlo Ferrari, Daniela Francisci, Katia Casinelli, Roberto Ganga, Chiara Costa, Alessandra Mangia, Francesco Paolo Russo, Filippo Matarazzo, Giuseppe Mazzella, Maurizio Mazzeo, Massimo Memoli, Marzia Montalbano, Giuseppe Montalto, Alessandro Pieri, Nicola Passariello, Antonio Picciotto, Antonello Pietrangelo, Mario Pirisi, Tiziana Quirino, Giovanni Raimondo, Gian Ludovico Rapaccini, Giuliano Rizzardini, Mario Rizzetto, Maurizio Russello, Giuseppe Sabusco, Teresa Santantonio, Giorgio Soardo, Alessandri Amedea, Gabriella Verucchi, Francesco Vinelli, Anna Linda Zignego, Massimo Zuin, Antonio Ascione, Maria Vinci, Maria Graziella Pigozzi, Paolo Tundo, Giorgio Maria Saracco, Pietro Amoroso, Massimo Andreoni, Cosimo Colletta, Elke Erne, Angelo Salomone Megna, Alberto Biglino, Piergiorgio Chiriaco, Giuseppe Foti, Giancarlo Spinzi, Emilio D'amico, …], Foster G.R., Coppola C., Derbala M., Ferenci P., Orlandini A., Reddy K.R., Tallarico L., Shiffman M.L., Ahlers S., Bakalos G., Hassanein T., Basho J., Shabanaj G., Harxhi A., Debzi N., Afredj N., Guessab N., Mahindad N., Mahiou H., Aissaoui M., Al Qameesh J., Al Ghandoor Z., Assene C., Bastens B., Brixko C., Cool M., De Galocsy C., Delwaide J., George C., Laukens P., Lefebvre V., Mulkay J.-P., Nevens F., Servais B., Van Vlierberghe H., Horsmans Y., Henrion J., Sprengers D., Michielsen P., Bourgeois S., Lasser L., Langlet P., Robaeys G., Martinet J.-P., Warzee P., Hoste P., Reynaert H., Juriens I., Decaestecker J., Van Der Meersch F., Janssens F., Ahmetagic S., Verhaz A., Bevanda M., Calkic L., Ibrahimpasic N., Mesihovic R., Mello C.E., Ruiz F.J., Junior E.M., Ferraz M.L., Silva G., Mendes C., Lyra A., Silva M.H., Gomide G., Fernandes J.C., Pereira P., Correa M.C., Teixeira R., Yousry A., Hanno A., Gabr M., Omar A., Esmat G., Karatapanis S., Nikolopoulou V., Giannoulis G., Manolakopoulos S., Elefsiniotis I., Drakoulis C., Dimitroulopoulos D., Kanatakis S., Ketikoglou I., Mimidis K., Evgenidis N., Akriviades E., Vafiadi-Zoubouli I., Tsianos E., Mela M., Orfanou E., Mousoulis G., Karagiannis I., Manesis E., Varga M., Nemesanszky E., Fried K., Schuller J., Szalay F., Lengyel G., Tornai I., Banyai T., Lesch M., Nagy I., Gervain J., Tusnadi A., Schneider F., Szentgyorgyi L., Hunyady B., Vincze A., Tolvaj G., Varkonyi I., Makkai E., Enyedi J., Racz I., Hausinger P., Vaczi Z., Patai A., Ozsvar Z., Lakner L., Ribiczey P., Bhalla A., Somani S., Luaia R., Rao P., Philip M., Lawate P., Nagral A., Sood A., Parikh S., Merat S., Nassiri-Toosi M., Alavian S.-M., Zali M.R., Daryani N.E., Drenaggi D., Attili A.F., Bandiera F., Bassi P., Bellati G., Bellantani S., Brunetto M., Bruno S., Castelli F., Castellacci R., Cattelan A.M., Colombo M., Craxi A., D'angelo S., Colombo S., Demelia L., Di Perri G., Di Giacomo A., Ferrari C., Francisci D., Casinelli K., Ganga R., Costa C., Mangia A., Russo F.P., Matarazzo F., Mazzella G., Mazzeo M., Memoli M., Montalbano M., Montalto G., Pieri A., Passariello N., Picciotto A., Pietrangelo A., Pirisi M., Quirino T., Raimondo G., Rapaccini G.L., Rizzardini G., Rizzetto M., Russello M., Sabusco G., Santantonio T., Soardo G., Amedea A., Verucchi G., Vinelli F., Zignego A.L., Zuin M., Ascione A., Vinci M., Pigozzi M.G., Tundo P., Saracco G.M., Amoroso P., Andreoni M., Colletta C., Erne E., Megna A.S., Biglino A., Chiriaco P., Foti G., Spinzi G., D'amico E., Paik S.W., Ahn S.-H., Lee Y.N., Kim Y., Yang J., Han S.Y., Varghese R., Al Gharabally A., Askar H., Sharara A., Yaghi C., Abou Rached A., Houmani Z., Zaarour F., Dohaibi A., Ivanovski L., Joksimovic N., Abbas Z., Memon S., Mohsin A., Masood S., Hashmi Z., Halota W., Deron Z., Mazur W., Flisiak R., Lipczynski A., Musialik J., Piekarska A., Augustyniak K., Baka-Cwierz B., Simon K., Gietka A., Berak H., Sieklucki J., Radowska D., Szlauer B., Piekos T., Olszok I., Jablkowski M., Orszulak G., Warakomska I., Aleixo M.J., Valente C., Macedo G., Sarmento-Castro R., Roxo F., Faria T., Mansinho K., Velez J., Ramos J.P., Guerreiro H., Alberto S., Monteverde C., Serejo F., Peixe P., Malhado J., Curescu M., Streinu-Cercel A., Caruntu F., Livia H., Preotescu L., Arama V., Ancuta I., Gheorghe L., Stanciu C., Trifan A., Acalovschi M., Andreica V., Pascu O., Lencu M., Sporea I., Olteanu D., Ionita-Radu F., Fierbinteanu-Braticevici C., Motoc A., Silaghi R., Musat M., Coman F., Stan M., Cijevschi C., Miftode E., Delic D., Jesic R., Nozic D., Svorcan P., Fabri M., Konstantinovic L., Pelemis M., Jankovic G., Todorovic Z., Nagorni A., Kupcova V., Skladany L., Szantova M., Krkoska D., Jarcuska P., Schreter I., Oltman M., Bocakova J., Bunganic I., Holoman J., Giguere A., Abdou A.M.S., UCL - SSS/IREC-Institut de recherche expérimentale et clinique, UCL - SSS/IREC/GAEN-Pôle d'Hépato-gastro-entérologie, and UCL - (SLuc) Service de gastro-entérologie
- Subjects
Genetics and Molecular Biology (all) ,Male ,Chronic Hepatitis ,Hepacivirus ,Ribavirin/adverse effects ,Asthenia/chemically induced ,Polyethylene Glycol ,Biochemistry ,Polyethylene Glycols ,Body Mass Index ,Chronic Liver Disease ,0302 clinical medicine ,Neutropenia/chemically induced ,Interferon-alpha/adverse effects ,Medicine ,Chronic ,lcsh:Science ,Liver Diseases ,virus diseases ,Antiviral Agents/adverse effects ,Cohort ,Science & Technology - Other Topics ,030211 gastroenterology & hepatology ,Drug Therapy, Combination ,Cohort study ,Human ,medicine.medical_specialty ,Alpha interferon ,Gastroenterology and Hepatology ,Antiviral Agents ,Microbiology ,Dose-Response Relationship ,03 medical and health sciences ,Pharmacotherapy ,Hepatitis C, Chronic/drug therapy ,Dose Prediction Methods ,Drug Therapy ,Anemia/chemically induced ,Humans ,Hemoglobin ,Aged ,Medicine and health sciences ,Biochemistry, Genetics and Molecular Biology (all) ,Hepaciviru ,Science & Technology ,Dose-Response Relationship, Drug ,Flaviviruses ,lcsh:R ,Organisms ,Biology and Life Sciences ,Proteins ,medicine.disease ,digestive system diseases ,chemistry ,Agricultural and Biological Sciences (all) ,Withholding Treatment ,Asthenia ,Immunology ,Proportional Hazards Model ,lcsh:Q ,Human medicine ,RNA viruses ,Physiology ,lcsh:Medicine ,Peginterferon-alfa ,Polyethylene Glycols/adverse effects ,Adult ,Anemia ,Cohort Studies ,Female ,Hepatitis C, Chronic ,Host-Pathogen Interactions ,Interferon-alpha ,Middle Aged ,Neutropenia ,Outcome Assessment (Health Care) ,Proportional Hazards Models ,RNA, Viral ,Recombinant Proteins ,Ribavirin ,Medicine (all) ,chemistry.chemical_compound ,Outcome Assessment, Health Care ,Medicine and Health Sciences ,030212 general & internal medicine ,Viral ,Pathology and laboratory medicine ,Multidisciplinary ,biology ,Hepatitis C virus ,Pharmaceutics ,Hepatitis C ,Hematology ,Recombinant Protein ,Outcome Assessment (Health Care)/methods ,Medical microbiology ,Host-Pathogen Interaction ,Multidisciplinary Sciences ,Physiological Parameters ,Research Design ,Combination ,Viruses ,Drug ,Pathogens ,Host-Pathogen Interactions/drug effects ,Research Article ,Clinical Research Design ,Research and Analysis Methods ,Internal medicine ,Recombinant Proteins/adverse effects ,RNA, Viral/blood ,Antiviral Agent ,business.industry ,Body Weight ,Hepacivirus/drug effects ,Viral pathogens ,biology.organism_classification ,Hepatitis viruses ,Microbial pathogens ,RNA ,Adverse Events ,Cohort Studie ,business - Abstract
Background: Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained settings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice. Methods: A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48 weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA
- Published
- 2015
10. Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
- Author
-
Idar Lygren, Jonas Koch, Severine Vermeire, Geert DʼHaens, Filip Baert, Jørgen Jahnsen, Inger Camilla Solberg, Edouard Louis, Fernand Fontaine, Tore Grimstad, Roald Torp, Lars Normann Karlsen, Olivier Dewit, D Staessen, Martine De Vos, Jean-Claude R J Coche, Fazia Mana, Guy Lambrecht, Vinciane Muls, Maja Noman, Thomas de Lange, Bert Vander Cruyssen, Philippe M R Potvin, Gert A. Van Assche, Pieter Hindryckx, André Van Gossum, Magne Henriksen, Cool M, Jacques Belaiche, Jo G P Vandervoort, Jean-Marc Maisin, Denis Franchimont, Eirik Kittang, Bart Neuville, Arnaud Collard, Philippe Van Hootegem, Tom G. Moreels, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, and Gastroenterology and Hepatology
- Subjects
Adult ,Male ,medicine.medical_specialty ,Enzyme-Linked Immunosorbent Assay ,Inflammatory bowel disease ,Gastroenterology ,Feces ,Young Adult ,fluids and secretions ,Maintenance therapy ,Recurrence ,Internal medicine ,medicine ,Humans ,Immunology and Allergy ,Longitudinal Studies ,Prospective Studies ,Colitis ,Prospective cohort study ,Sigmoidoscopy ,Aged ,biology ,business.industry ,Anti-Inflammatory Agents, Non-Steroidal ,Remission Induction ,C-reactive protein ,Antibodies, Monoclonal ,Middle Aged ,Prognosis ,medicine.disease ,Ulcerative colitis ,Infliximab ,Surgery ,Area Under Curve ,biology.protein ,Colitis, Ulcerative ,Female ,Human medicine ,Calprotectin ,business ,Leukocyte L1 Antigen Complex ,Biomarkers ,Follow-Up Studies ,medicine.drug - Abstract
Background:This study examined whether fecal calprotectin can be used in daily practice as a marker to monitor patients with ulcerative colitis (UC) receiving infliximab maintenance therapy.Methods:This prospective multicenter study enrolled adult patients with UC in clinical remission under infliximab maintenance therapy. Fecal calprotectin levels were measured every 4 weeks. Sigmoidoscopies were performed at inclusion and at study end. Relapse was defined as a clinical need for change in treatment or an endoscopic Mayo subscore of 2 at week 52. Sustained deep remission was defined as a partial Mayo score 300 mg/kg) already 3 months before the flare. Further receiver operator curve analysis suggested that a calprotectin level >300 mg/kg had a reasonable sensitivity (58.3%) and specificity (93.3%) to model flare. Two consecutive calprotectin measurements of >300 mg/kg with 1-month interval were identified as the best predictor of flare (61.5% sensitivity and 100% specificity).Conclusions:Fecal calprotectin can be used in daily practice to monitor patients with UC receiving infliximab maintenance therapy. Two consecutive measurements >300 mg/kg is more specific than a single measurement for predicting relapse.
- Published
- 2013
11. Alternative Treatment Options in Colorectal Cancer Patients With 5–Fluorouracil- or Capecitabine-Induced Cardiotoxicity
- Author
-
Guido Deboever, Nick Hiltrop, Cool M, and Guy Lambrecht
- Subjects
Oncology ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,Heart Diseases ,Colorectal cancer ,Deoxycytidine ,Tegafur ,Capecitabine ,Internal medicine ,medicine ,Dihydropyrimidine dehydrogenase ,Animals ,Humans ,Cardiotoxicity ,business.industry ,Gastroenterology ,Cardiovascular Agents ,medicine.disease ,Regimen ,Fluorouracil ,Colorectal Neoplasms ,business ,Raltitrexed ,medicine.drug - Abstract
Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because it carries a high risk of recurrence of the cardiac symptoms and prophylactic treatment is not always protective. Possible alternative treatment options to be considered are to replace the oral capecitabine or intravenous 5-FU by a 5-FU bolus regimen, by uracil-tegafur or tegafur/gimeracil/oteracil, both oral fluoropyrimidines combining a 5-FU prodrug with a dihydropyrimidine dehydrogenase (DPD) inhibitor, or by raltitrexed, a thymidilate synthase inhibitor whose metabolism is independent of DPD. Patients with advanced colorectal cancer and fluoropyrimidine-induced cardiotoxicity can be treated with other non-fluoropyrimidine related chemotherapy, either as a single agent, combined, or in combination with biological agents. In this report we discuss the different alternative treatment options.
- Published
- 2013
12. Experience with Direct Acting Agents for the Treatment of Hepatitis C in Flanders
- Author
-
Bielen, Rob, Robaeys, Geert, Cool, M., Decaestecker, J., Janssens, F., George, C., Laleman, W., Verslype, C., Cassiman, David, Van der Merwe, S., and Nevens, F.
- Subjects
virus diseases ,digestive system diseases - Abstract
Introduction: Hepatitis C (HCV) remains one of the main causes of chronic liver disease worldwide. The impact of chronic HCV on the long-term ranges widely, from minimal histologic changes to decompensated cirrhosis or hepatocellular carcinoma. These last years, the development of direct acting antivirals have revolutionized HCV care. We present the experience in the KU Leuven affiliated hospitals with the latest generation of direct acting antivirals. These are therapies without concomitant use of interferon, such as simeprevir, sofosbuvir, daclatasvir, and ombitasvir/paritaprevir ritonavir – dasabuvir. Aim Goal of this abstract is to demonstrate the safety and efficacy of the newest generation of direct acting antivirals in the general population in Belgium (the KU Leuven affiliated hospitals). Methods A national retrospective, interventional cohort study conducted between December 2013 and November 2015 in 6 Belgian centers during which patients infected with HCV were treated with the new regimes of DAA. All centers were experienced in treating HCV. In case antiviral treatment was started data were collected in a central database, with main focus on treatment outcome and side effects. Results and discussion In total, 134 patients (age 58 ± 12 years) were treated with one of the newest generation DAAs. All patients had multiple comorbidities, with an average rate of 1.55 ± 1.6. These were highest in the simeprevir/sofosbuvir group. HCV genotype 1b was most prevalent. 45.9% of the patients were treatment naïve, and 38.7% % was once treated before. 59 patients were treated with daclatasvir/sofosbuvir ± ribavirin, 48 with simeprevir/sofosbuvir ± ribavirin, and 27 with ombitasvir/ paritaprevir, ritonavir – dasabuvir ± ribavirin. Treatment is completed in only 60.4% of all patients. Moreover, only 42.5% were treated long enough so they could achieve SVR. From this group, almost everyone obtained SVR (96.5%). Subanalysis showed an SVR-rate of 100% (10/10) in the daclatasvir/sofosbuvir ± ribavirin group, 92.6% (25/27) in the simeprevir/sofosbuvir ± ribavirin group, and 100% (20/20) in the ombitasvir/ paritaprevir, ritonavir – dasabuvir ± ribavirin group. Side effects were present in 49.3 % of the total population, most frequent were an increase in fatigue and skin eruptions. Only in 9.7 %, this required a change in therapy. Ribavirin was lowered in dose or stopped in these cases. These are preliminary results, we will present larger data at the time of the congress. Conclusion Real-life experience with DAAs in Belgium shows comparable excellent results in achieving SVR for the treatment of HCV. Side effects were frequent, but rarely cause a need for therapy change. This study is part of the Limburg Clinical Research Program (LCRP) UHasselt-ZOL-Jessa, supported by the foundation Limburg SterkMerk, Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital.
- Published
- 2016
13. The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without pegylated interferon: a Belgian experience
- Author
-
Bielen, R., primary, Moreno, C., additional, Van Vlierberghe, H., additional, Bourgeois, S., additional, Mulkay, J.-P., additional, Francque, S., additional, Verlinden, W., additional, Brixko, C., additional, Decaestecker, J., additional, De Galocsy, C., additional, Janssens, F., additional, Cool, M., additional, Van Steenkiste, C., additional, D’heygere, F., additional, Wuyckens, K., additional, Nevens, F., additional, and Robaeys, G., additional
- Published
- 2017
- Full Text
- View/download PDF
14. Metallic contaminants in street soils of Moncton, New Brunswick, Canada
- Author
-
Cool, M., Marcoux, F., Paulin, A., and Mehra, M. C.
- Published
- 1980
- Full Text
- View/download PDF
15. De bestrijding der werkloosheidsgevolgen in Nederlandsch-Indie gedurende 1930–1936
- Author
-
Cool, M. F. J.
- Published
- 1938
- Full Text
- View/download PDF
16. Perils of construction cost estimating reduced with software system
- Author
-
Cool, M. W.
- Abstract
Aussi disponsible en français: Un nouveau logiciel facilite l'estimation des coûts de construction
- Published
- 1996
17. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.
- Author
-
Di Cola, G, primary, Cool, M H, additional, and Accili, D, additional
- Published
- 1997
- Full Text
- View/download PDF
18. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice.
- Author
-
Accili, D, primary, Fishburn, C S, additional, Drago, J, additional, Steiner, H, additional, Lachowicz, J E, additional, Park, B H, additional, Gauda, E B, additional, Lee, E J, additional, Cool, M H, additional, Sibley, D R, additional, Gerfen, C R, additional, Westphal, H, additional, and Fuchs, S, additional
- Published
- 1996
- Full Text
- View/download PDF
19. Molecular and genetic analysis of the yeast early meiotic recombination genes REC102 and REC107/MER2
- Author
-
Cool, M, primary and Malone, R E, additional
- Published
- 1992
- Full Text
- View/download PDF
20. Transnasal Butorphanol
- Author
-
ABBOUD, T. K., primary, ZHU, J., additional, GANGOLLY, J., additional, LONGHITANO, M., additional, SWART, F., additional, MAKAR, A., additional, CHU, G., additional, COOL, M., additional, MANTILLA, M., additional, KURTZ, N., additional, and REICH, L., additional
- Published
- 1991
- Full Text
- View/download PDF
21. Isolation of mutants defective in early steps of meiotic recombination in the yeast Saccharomyces cerevisiae.
- Author
-
Malone, R E, primary, Bullard, S, additional, Hermiston, M, additional, Rieger, R, additional, Cool, M, additional, and Galbraith, A, additional
- Published
- 1991
- Full Text
- View/download PDF
22. Transnasal butorphanol: a new method for pain relief in post-cesarean section pain
- Author
-
ABBOUD, T. K., primary, ZHU, J., additional, GANGOLLY, J., additional, LONGHITANO, M., additional, SWART, F., additional, MAKAR, A., additional, CHU, G., additional, COOL, M., additional, MANTILLA, M., additional, KURTZ, N., additional, and REICH, L., additional
- Published
- 1991
- Full Text
- View/download PDF
23. Die Zukunftsentwicklung der Java-Zucker-Industrie unter dem Einfluß der Selbstabschließungstendenzen auf dem Weltmarkt Anno von Gebhardt
- Author
-
Cool, M. F. J.
- Published
- 1939
24. A general upstream binding factor for genes of the yeast translational apparatus.
- Author
-
Huet, J., Cottrelle, P., Cool, M., Vignais, M.L., Thiele, D., Marck, C., Buhler, J.M., Sentenac, A., and Fromageot, P.
- Abstract
Fractionation of yeast extracts on heparin‐agarose revealed the presence of a DNA footprinting activity that interacted specifically with the 5′‐upstream region of TEF1 and TEF2 genes coding for the protein synthesis elongation factor EF‐1 alpha, and of the ribosomal protein gene RP51A. The protected regions encompassed the conserved sequences ‘HOMOL1’ (AACATC TA CG T A G CA) or RPG‐box (ACCCATACATT TA) previously detected 200‐400 bp upstream of most of the yeast ribosomal protein genes examined. Two types of protein‐DNA complexes were separated by a gel electrophoresis retardation assay. Complex 1, formed on TEF1, TEF2 and RP51A 5′‐flanking region, was correlated with the protection of a 25‐bp sequence. Complex 2, formed on TEF2 or RP51A probes at higher protein concentrations, corresponded to an extended footprint of 35‐40 bp. The migration characteristics of the protein‐DNA complexes and competition experiments indicated that the same component(s) interacted with the three different promoters. It is suggested that this DNA factor(s) is required for activation and coordinated regulation of the whole family of genes coding for the translational apparatus.
- Published
- 1985
- Full Text
- View/download PDF
25. TRANSNASAL ANALGESICS
- Author
-
Abboud, T. K., primary, Zhu, J., additional, Gangolly, J., additional, Longhitano, M., additional, Swart, F., additional, Silao, P., additional, Makar, A., additional, Zeraan, R., additional, Chu, G., additional, Cool, M., additional, Mantilla, M., additional, Kurtz, N., additional, and Reich, L., additional
- Published
- 1988
- Full Text
- View/download PDF
26. Analgesic efficacy and safety of intranasally administered butorphanol in post-partum episiotomy pain
- Author
-
Kurtz, N., primary, Chu, G., additional, Cool, M., additional, Abboud, T., additional, and Joyce, T. H., additional
- Published
- 1987
- Full Text
- View/download PDF
27. The MDCT-scan as an important tool in the management of relapsing, overt upper gastrointestinal bleeding: letter to the editor.
- Author
-
De Beul, P., Castelein, T., Claikens, B., Roelandt, W., Lambrecht, G., Cool, M., Defreyne, L., and Deboever, G.
- Published
- 2014
28. Metallic Contaminants in Street Soils of Moncton, New Brunswick, Canada
- Author
-
Mehra, M. C., Marcoux, F., Cool, M., and Paulin, A.
- Subjects
SOILS - Published
- 1980
29. CROSS-WORD ENIGMA.--No. 9.
- Author
-
COOL, M. A.
- Published
- 1870
30. NEF-Induced HIV-Associated Nephropathy Through HCK/LYN Tyrosine Kinases.
- Author
-
Hu C, Priceputu E, Cool M, Chrobak P, Bouchard N, Forestier C, Lowell CA, Bénichou S, Hanna Z, Royal V, and Jolicoeur P
- Subjects
- Mice, Humans, Animals, Protein-Tyrosine Kinases metabolism, Mice, Transgenic, Tyrosine, src-Family Kinases, Proto-Oncogene Proteins c-hck, AIDS-Associated Nephropathy genetics, AIDS-Associated Nephropathy pathology, HIV Infections complications
- Abstract
HIV-1-associated nephropathy (HIVAN) is a severe complication of HIV-1 infection. To gain insight into the pathogenesis of kidney disease in the setting of HIV, a transgenic (Tg) mouse model [CD4C/HIV-negative regulator factor (Nef)] was used in which HIV-1 nef expression is under control of regulatory sequences (CD4C) of the human CD4 gene, thus allowing expression in target cells of the virus. These Tg mice develop a collapsing focal segmental glomerulosclerosis associated with microcystic dilatation, similar to human HIVAN. To identify kidney cells permissive to the CD4C promoter, CD4C reporter Tg lines were used. They showed preferential expression in glomeruli, mainly in mesangial cells. Breeding CD4C/HIV Tg mice on 10 different mouse backgrounds showed that HIVAN was modulated by host genetic factors. Studies of gene-deficient Tg mice revealed that the presence of B and T cells and that of several genes was dispensable for the development of HIVAN: those involved in apoptosis (Trp53, Tnfsf10, Tnf, Tnfrsf1b, and Bax), in immune cell recruitment (Ccl3, Ccl2, Ccr2, Ccr5, and Cx3cr1), in nitric oxide (NO) formation (Nos3 and Nos2), or in cell signaling (Fyn, Lck, and Hck/Fgr). However, deletion of Src partially and that of Hck/Lyn largely abrogated its development. These data suggest that Nef expression in mesangial cells through hematopoietic cell kinase (Hck)/Lck/Yes novel tyrosine kinase (Lyn) represents important cellular and molecular events for the development of HIVAN in these Tg mice., (Copyright © 2023 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
31. HIV-1 Nef Induces Hck/Lyn-Dependent Expansion of Myeloid-Derived Suppressor Cells Associated with Elevated Interleukin-17/G-CSF Levels.
- Author
-
Priceputu E, Cool M, Bouchard N, Caceres-Cortes JR, Lowell CA, Hanna Z, and Jolicoeur P
- Subjects
- Animals, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, CD4-Positive T-Lymphocytes virology, Cell Differentiation, Dendritic Cells immunology, Dendritic Cells metabolism, Dendritic Cells virology, Female, Granulocyte Colony-Stimulating Factor genetics, Granulocytes immunology, Granulocytes metabolism, Granulocytes pathology, HIV Infections metabolism, HIV Infections virology, HIV-1 immunology, Humans, Interleukin-17 genetics, Macrophages immunology, Macrophages metabolism, Macrophages virology, Mice, Mice, Inbred BALB C, Mice, Inbred C3H, Mice, Inbred C57BL, Mice, Transgenic, Monocytes immunology, Monocytes metabolism, Monocytes virology, Myeloid-Derived Suppressor Cells metabolism, Myeloid-Derived Suppressor Cells virology, Proto-Oncogene Proteins c-hck genetics, nef Gene Products, Human Immunodeficiency Virus genetics, src-Family Kinases genetics, Granulocyte Colony-Stimulating Factor metabolism, HIV Infections immunology, Interleukin-17 metabolism, Myeloid-Derived Suppressor Cells immunology, Proto-Oncogene Proteins c-hck metabolism, nef Gene Products, Human Immunodeficiency Virus metabolism, src-Family Kinases metabolism
- Abstract
Human immunodeficiency virus (HIV) or simian immunodeficiency virus (SIV) infection causes myelodysplasia, anemia, and accumulation of inflammatory monocytes (CD14
+ CD16+ ) through largely unknown cellular and molecular pathways. The mouse cells thought to be equivalent to human CD14+ CD16+ cells are CD11b+ Gr1+ myeloid-derived suppressor cells (MDSC). We used HIV transgenic (Tg) mouse models to study MDSC, namely, CD4C/Nef Tg mice expressing nef in dendritic cells (DC), pDC, CD4+ T, and other mature and immature myeloid cells and CD11c/Nef Tg mice with a more restricted expression, mainly in DC and pDC. Both Tg strains showed expansion of granulocytic and CD11b+ Gr1low/int cells with MDSC characteristics. Fetal liver cell transplantation revealed that this expansion was stroma-independent and abrogated in mixed Tg/non-Tg 50% chimera. Tg bone marrow (BM) erythroid progenitors were decreased and myeloid precursors increased, suggesting an aberrant differentiation likely driving CD11b+ Gr1+ cell expansion, apparently cell autonomously in CD4C/Nef Tg mice and likely through a bystander effect in CD11c/Nef Tg mice. Hck was activated in Tg spleen, and Nef-mediated CD11b+ Gr1+ cell expansion was abrogated in Hck/Lyn-deficient Nef Tg mice, indicating a requirement of Hck/Lyn for this Nef function. IL-17 and granulocyte colony-stimulating factor (G-CSF) were elevated in Nef Tg mice. Increased G-CSF levels were normalized in Tg mice treated with anti-IL-17 antibodies. Therefore, Nef expression in myeloid precursors causes severe BM failure, apparently cell autonomously. More cell-restricted expression of Nef in DC and pDC appears sufficient to induce BM differentiation impairment, granulopoiesis, and expansion of MDSC at the expense of erythroid maturation, with IL-17→G-CSF as one likely bystander contributor. IMPORTANCE HIV-1 and SIV infection often lead to myelodysplasia, anemia, and accumulation of inflammatory monocytes (CD14+ CD16+ ), with the latter likely involved in neuroAIDS. We found that some transgenic (Tg) mouse models of AIDS also develop accumulation of mature and immature cells of the granulocytic lineage, decreased erythroid precursors, and expansion of MDSC (equivalent to human CD14+ CD16+ cells). We identified Nef as being responsible for these phenotypes, and its expression in mouse DC appears sufficient for their development through a bystander mechanism. Nef expression in myeloid progenitors may also favor myeloid cell expansion, likely in a cell-autonomous way. Hck/Lyn is required for the Nef-mediated accumulation of myeloid cells. Finally, we identified G-CSF under the control of IL-17 as one bystander mediator of MDSC expansion. Our findings provide a framework to determine whether the Nef>Hck/Lyn>IL-17>G-CSF pathway is involved in human AIDS and whether it represents a valid therapeutic target.- Published
- 2021
- Full Text
- View/download PDF
32. Comorbidities and concomitant medications in patients with chronic hepatitis C virus infection receiving second-generation direct-acting antiviral regimens in Belgium: an observational study.
- Author
-
Bourgeois S, Mulkay JP, Cool M, Verhelst X, Robaeys G, Lasser L, Lefebvre V, Colle I, Van Steenkiste C, Decaestecker J, Coulon S, Venken K, and Vanwolleghem T
- Subjects
- Adult, Antiviral Agents adverse effects, Belgium epidemiology, Hepacivirus, Humans, Coinfection, Diabetes Mellitus, Type 2 drug therapy, HIV Infections, Hepatitis C drug therapy, Hepatitis C, Chronic drug therapy, Hepatitis C, Chronic epidemiology
- Abstract
Objective: To describe comorbidities and concomitant medications in patients initiating treatment for hepatitis C virus (HCV) infection with direct-acting antiviral (DAA) regimens in Belgium., Methods: This was a noninterventional, observational, multicenter study of data from patient charts. Adult patients with HCV infection receiving second-generation DAA therapy were included. Comorbidities were assessed at the time of HCV treatment initiation. Concomitant medications were recorded at the time of diagnosis and at treatment initiation. Potential clinically relevant drug-drug interactions (DDIs) were assessed based on information available at www.hep-druginteractions.org. The primary objective was to describe concomitant medication use ; secondary objectives were to describe modifications in concomitant therapies and comorbidities., Results: 405 patients were included. A total of 956 comorbidities were reported by 362 patients (median, 2 ; range, 0-15). The most common comorbidities were hypertension (27.2%) ; HIV coinfection (22.5%), and type 2 diabetes mellitus (14.3%). Overall, 1455 concomitant medications were being taken by 365 patients (90.1% ; median, 3 ; range 0-16). The most common concomitant medications were psycholeptics (28.6%), antiviral agents (24.2%), and medications for acid-related disorders (21.0%) Overall, 74/365 (20.3%) patients receiving a concomitant medication required an adaptation to their concomitant medication. The medications that most frequently required change were drugs for acid-related disorders (n = 14) and antiviral drugs (n = 5) ; those that were most frequently stopped were lipid-modifying drugs (n = 25) and drugs for acid-related disorders (n = 13)., Conclusion: Physicians are aware of the potential for DDIs with DAAs, but improved alignment between clinical practice and theoretical recommendations is required., (© Acta Gastro-Enterologica Belgica.)
- Published
- 2021
- Full Text
- View/download PDF
33. Ascaris lumbricoides: challenges in diagnosis, treatment and prevention strategies in a European refugee camp.
- Author
-
Claus PE, Ceuppens AS, Cool M, and Alliet G
- Subjects
- Aged, Animals, Female, France, Humans, Hygiene, Sanitation, Ascariasis diagnosis, Ascariasis drug therapy, Ascariasis prevention & control, Ascaris lumbricoides, Refugee Camps
- Abstract
Objectives: The roundworm Ascaris lumbricoides is one of the most prevalent parasites belonging to the class of the soil-transmitted helminths. Infections are most common in developing countries with a tropical climate where sanitation and hygiene are poor. However, prevalence of ascariasis in industrialized countries is increasing because of immigration and increasing number of refugees., Methods: We report a case of ascariasis in a female patient who was admitted to our hospital after she had left the informal refugee camp of Calais in the north of France., Results: After colonoscopic removal of the worm and treatment with mebendazole during three days the patient's symptoms had completely resolved. Medical treatment with benzimidazole derivatives is easy and inexpensive. To prevent parasitic infections in larger populations, mass drug administration should be repeated periodically and must be implemented along with additional measures such as improvements to water, sanitation and hygiene (WASH). These WASH programs have been proven to be highly effective, but access and follow-up are expensive and very difficult to organize in refugee camps, even in wealthy, industrialized countries., Conclusions: Despite being an old, well-known parasitic disease, ascariasis might reappear in certain populations at risk in industrialized countries. Detection, treatment and follow-up of these patients, and the organization of preventive measures remain challenging.
- Published
- 2018
- Full Text
- View/download PDF
34. Belgian experience with direct acting antivirals in people who inject drugs.
- Author
-
Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwolleghem T, Verlinden W, Brixko C, Decaestecker J, De Galocsy C, Janssens F, Cool M, Van Overbeke L, Van Steenkiste C, D'heygere F, Cools W, Nevens F, and Robaeys G
- Subjects
- Adult, Aged, Antiviral Agents pharmacology, Belgium epidemiology, Carbamates, Cohort Studies, Female, Hepacivirus drug effects, Humans, Imidazoles pharmacology, Imidazoles therapeutic use, Male, Middle Aged, Pyrrolidines, Retrospective Studies, Simeprevir pharmacology, Simeprevir therapeutic use, Sofosbuvir pharmacology, Sofosbuvir therapeutic use, Valine analogs & derivatives, Antiviral Agents therapeutic use, Hepatitis C drug therapy, Hepatitis C epidemiology, Substance Abuse, Intravenous drug therapy, Substance Abuse, Intravenous epidemiology
- Abstract
Background and Aim: Hepatitis C viral infection (HCV) has become a curable disease due to the development of direct acting antivirals (DAA). The WHO has set a target to eliminate HCV completely. Therefore, people who inject drugs (PWID) also need to be treated. In this study, we compared the real-life uptake and outcome of DAA treatment for HCV in PWID and non-PWID., Methods: We performed a nation-wide, retrospective cohort study in 15 hospitals. All patients who were treated with simeprevir-sofosbuvir, daclatasvir-sofosbuvir, or ombitasvir/paritaprevir ritonavir-dasabuvir between December 2013 and November 2015 were included., Results: The study population consisted of 579 patients: 115 PWID (19.9%) and 464 non-PWID (80.1%). Of the PWID 18 were active PWID (15.6%), 35 still received opiate substitution therapy (OST) (30.4%) and 62 were former PWID without OST (53.9%). PWID were more infected with genotype 1a and 3 (p=0.001). There were equal rates of side-effects (44.7% vs. 46.6%; p=0.847), similar rates of treatment completion (95.7% vs 98.1%; p=0.244) and SVR (93.0% vs 94.8%; p=0.430) between PWID and non-PWID, respectively., Conclusion: PWID, especially active users, are underserved for DAA treatment in real life in Belgium. Reimbursement criteria based on fibrosis stage make it difficult to treat PWID. Treatment adherence is similar in PWID and the general population, even in patients with active abuse. DAA were safe and effective in PWID despite the higher prevalence of difficult-to-treat genotypes. Based on these data more efforts to treat PWID are needed and policy changes are necessary to reach the WHO targets., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
35. Hemosuccus pancreaticus caused by rupture of a splenic artery pseudoaneurysm complicating chronic alcoholic pancreatitis: an uncommon cause of gastrointestinal bleeding.
- Author
-
Hiltrop N, Vanhauwaert A, Palmers PJ, Cool M, Deboever G, and Lambrecht G
- Subjects
- Chronic Disease, Female, Humans, Middle Aged, Aneurysm, False complications, Aneurysm, Ruptured complications, Gastrointestinal Hemorrhage etiology, Pancreatitis, Alcoholic complications, Splenic Artery
- Abstract
We present a case of a 52-year old female patient with intermittent gastrointestinal bleeding and iron deficiency anaemia. Repeated endoscopic investigation revealed no diagnosis, but contrast-enhanced computed tomography showed a splenic artery pseudo-aneurysm secondary to chronic alcoholic pancreatitis. A distal pancreatectomy and splenectomy was performed. Hemosuccus pancreaticus is an uncommon cause of gastrointestinal bleeding, most frequently associated with chronic pancreatitis. Erosion of a peripancreatic artery by a pseudocyst can cause a pseudoaneurysm and rupture occurs in up to 10% of the cases. Bleeding from a pseudocyst wall or rupture of an atherosclerotic or traumatic aneurysm is rare. Angiography, contrast-enhanced computed tomography and endoscopic findings can be diagnostic in the majority of cases. Angiographic embolization or surgery are both therapeutic options depending on underlying nonvascular pancreas related indications requiring surgery. We discuss diagnostic pitfalls and current therapeutic strategies in the management of this disease., (© Acta Gastro-Enterologica Belgica.)
- Published
- 2015
36. CMV gastritis in the immunocompetent host.
- Author
-
Claeys M, Cool M, Lambrecht GL, Hertveldt K, Alliet G, and Deboever G
- Subjects
- Aged, Humans, Male, Cytomegalovirus Infections complications, Cytomegalovirus Infections diagnosis, Gastritis diagnosis, Gastritis virology
- Published
- 2015
37. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
- Author
-
Deboever G, Hiltrop N, Cool M, and Lambrecht G
- Subjects
- Animals, Capecitabine, Deoxycytidine adverse effects, Heart Diseases chemically induced, Humans, Antimetabolites, Antineoplastic adverse effects, Cardiovascular Agents therapeutic use, Colorectal Neoplasms drug therapy, Deoxycytidine analogs & derivatives, Fluorouracil adverse effects, Fluorouracil analogs & derivatives, Heart Diseases prevention & control
- Abstract
Most chemotherapy regimens in colorectal cancer treatment are 5-fluorouracil (5-FU)/leucovorin or capecitabine-based. Cardiotoxicity is a less common but potentially lethal complication of 5-FU or capecitabine treatment, and some physicians might be unfamiliar with treatment alternatives. Rechallenging should be avoided because it carries a high risk of recurrence of the cardiac symptoms and prophylactic treatment is not always protective. Possible alternative treatment options to be considered are to replace the oral capecitabine or intravenous 5-FU by a 5-FU bolus regimen, by uracil-tegafur or tegafur/gimeracil/oteracil, both oral fluoropyrimidines combining a 5-FU prodrug with a dihydropyrimidine dehydrogenase (DPD) inhibitor, or by raltitrexed, a thymidilate synthase inhibitor whose metabolism is independent of DPD. Patients with advanced colorectal cancer and fluoropyrimidine-induced cardiotoxicity can be treated with other non-fluoropyrimidine related chemotherapy, either as a single agent, combined, or in combination with biological agents. In this report we discuss the different alternative treatment options., (Copyright © 2013 Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
38. No detectable XMRV in subjects with chronic fatigue syndrome from Quebec.
- Author
-
Cool M, Bouchard N, Massé G, Laganière B, Dumont A, Hanna Z, Phaneuf D, Morisset R, and Jolicoeur P
- Subjects
- Cell Line, Tumor, Cells, Cultured, Cohort Studies, DNA, Viral genetics, Fatigue Syndrome, Chronic diagnosis, Female, Humans, Leukocytes, Mononuclear virology, Male, Quebec, Xenotropic murine leukemia virus-related virus genetics, Fatigue Syndrome, Chronic virology, Xenotropic murine leukemia virus-related virus isolation & purification
- Abstract
We investigated the presence of XMRV in a cohort of Quebec patients with chronic fatigue syndrome (CFS). DNA was purified from activated peripheral blood mononuclear cells (PBMCs) and PCR was used to detect XMRV gag and env in 72 patients. Anti-XMRV antibodies were searched in sera of 62 patients by Western blot analysis. Attempts to detect XMRV antigens was made, using immunofluorescence with Gag anti-p30 antiserum on activated PBMC from 50 patients. Plasma viremia was measured by RT-PCR on 9 subjects. Finally, detection of infectious virus in 113 CFS subjects was made by co-culture of PHA+IL-2 activated PBMC with human LNCaP carcinoma cells, and by infecting the same susceptible cells with plasma, using a reverse transcriptase (RT) assay as a readout in both experiments. No detection of XMRV footprints nor infectious virus was detected with any of the approaches, in any of the tested individuals., (Copyright © 2011 Elsevier Inc. All rights reserved.)
- Published
- 2011
- Full Text
- View/download PDF
39. Endobronchial metastases from colorectal cancer.
- Author
-
Deboever G, Hiltrop N, Desmet G, Hertveldt K, Cool M, and Lambrecht G
- Subjects
- Aged, 80 and over, Bronchial Neoplasms diagnosis, Bronchoscopy, Carcinoma diagnosis, Colorectal Neoplasms diagnostic imaging, Diagnosis, Differential, Humans, Male, Neoplasm Metastasis, Tomography, X-Ray Computed, Bronchial Neoplasms secondary, Carcinoma secondary, Colorectal Neoplasms pathology
- Published
- 2011
40. Overexpression of Notch1 ectodomain in myeloid cells induces vascular malformations through a paracrine pathway.
- Author
-
Li X, Calvo E, Cool M, Chrobak P, Kay DG, and Jolicoeur P
- Subjects
- Animals, Fetal Tissue Transplantation, Liver blood supply, Liver pathology, Liver Diseases pathology, Liver Transplantation, Macrophages, Peritoneal physiology, Macrophages, Peritoneal transplantation, Mice, Mice, Nude, Mice, Transgenic, Paracrine Communication, Peripheral Vascular Diseases pathology, Protein Structure, Tertiary genetics, Receptor, Notch1 biosynthesis, Up-Regulation, Liver Diseases genetics, Myeloid Cells physiology, Peripheral Vascular Diseases genetics, Receptor, Notch1 genetics
- Abstract
We previously reported that truncation of Notch1 (N1) by provirus insertion leads to overexpression of both the intracellular (N1(IC)) and the extracellular (N1(EC)) domains. We produced transgenic (Tg) mice expressing N1(EC) in T cells and in cells of the myeloid lineage under the regulation of the CD4 gene. These CD4C/N1(EC) Tg mice developed vascular disease, predominantly in the liver: superficial distorted vessels, cavernae, lower branching of parenchymal vessels, capillarized sinusoids, and aberrant smooth muscle/endothelial cell topography. The disease developed in lethally irradiated normal mice transplanted with Tg bone marrow or fetal liver cells as well as in Rag-/- Tg mice. In nude mice transplanted with fetal liver cells from (ROSA26 x CD4C/N1(EC)) F1 Tg mice, abnormal vessels were of recipient origin. Transplantation of Tg peritoneal macrophages into normal recipients also induced abnormal vessels. These Tg macrophages showed impaired functions, and their conditioned medium inhibited the proliferation of liver sinusoid endothelial cells in vitro. The Egr-1 gene and some of its targets (Jag1, FIII, FXIII-A, MCP-1, and MCP-5), previously implicated in hemangioma or vascular malformations, were overexpressed in Tg macrophages. These results show that myeloid cells can be reprogrammed by N1(EC) to induce vascular malformations through a paracrine pathway.
- Published
- 2007
- Full Text
- View/download PDF
41. Fine allelotyping of Erbb2-induced mammary tumors in mice reveals multiple discontinuous candidate regions of tumor-suppressor loci.
- Author
-
Cool M, Depault F, and Jolicoeur P
- Subjects
- Animals, Loss of Heterozygosity, Mice, Microsatellite Repeats, Polymerase Chain Reaction, Terminology as Topic, Alleles, Genes, Tumor Suppressor, Genes, erbB-2, Mammary Neoplasms, Experimental genetics
- Abstract
Loss of heterozygosity (LOH) at human chromosome bands 1p32-36 and 10q23-26 is frequent in various human tumors, including breast cancers, and is thought to reflect the loss of tumor-suppressor genes (TSGs). To map such genes, high-resolution LOH analysis was performed on 93 Erbb2-induced mammary tumors from (BALB/c x C57BL/6) F1 MMTV/Erbb2 transgenic mice. A panel of 24 microsatellite markers specific to the region of mouse chr4, homologous to human 1p31-36, and 16 markers specific to the mouse chr19 region, homologous to human 10q23-26 were used. In addition, lower-density mapping was performed on the remaining portion of mouse chr4 [homologous to human 9p13, 9p21-24, 9q21-22, 9q31-34 (12 markers)] and chr19 [homologous to 9q21, 9p24, 11q12-13 (9 markers)]. Several distinct, discrete, and discontinuous LOH regions flanked by areas of heterozygosity were identified, 22 on chr4 and 14 on chr19. Among these, 13 were mapped in the region of homology with human 1p31-36 (between D4Mit153 and D4Mit254) and 9 in the region of homology with human 10q23-26 (between D19Mit46 and D19Mit6). Although several LOH loci span a large interval, many are relatively short (1-4 Mb), and a few span an interval of <1 Mb. This allelotyping represents the highest density of LOH loci yet mapped in these chromosomal regions. The presence of numerous LOH regions in alternation with regions of heterozygosity, consistent with mitotic recombination as a mechanism for generating such a mosaic pattern, suggests the presence of several TSGs in these regions and should facilitate their identification.
- Published
- 2006
- Full Text
- View/download PDF
42. Dual pH monitoring to detect food and beverage artifacts.
- Author
-
Tack J, Cool M, and Sifrin D
- Subjects
- Electrodes, Implanted, Humans, Hydrogen-Ion Concentration, Monitoring, Ambulatory instrumentation, Artifacts, Beverages, Food, Monitoring, Ambulatory methods
- Published
- 2005
- Full Text
- View/download PDF
43. Characteristics and clinical relevance of proximal esophageal pH monitoring.
- Author
-
Cool M, Poelmans J, Feenstra L, and Tack J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Chi-Square Distribution, Esophagoscopy, Female, Humans, Hydrogen-Ion Concentration, Logistic Models, Male, Manometry, Middle Aged, Esophagus metabolism, Gastroesophageal Reflux diagnosis, Monitoring, Ambulatory methods
- Abstract
Objective: It is well established that various ENT disorders and symptoms may be a manifestation of gastroesophageal reflux disease (GERD). Measuring proximal esophageal acid exposure might be useful in the evaluation of patients with suspected reflux-related ENT manifestations, but the limited available data are conflicting. The aim of the present study was to study the determinants of proximal esophageal acid exposure (PR) and to evaluate the clinical usefulness of ambulatory proximal pH monitoring., Methods: Twenty healthy controls and 346 patients with suspected reflux disease underwent typical and atypical GERD symptom assessment, endoscopy, esophageal manometry and ambulatory combined dual esophageal pH, and Bilitec duodeno-gastro-esophageal reflux exposure (DGER) monitoring. The presence of pathological PR and its relation to symptom pattern and distal esophageal acid exposure (DR) and DGER exposure were analyzed., Results: Fifty-seven patients (16%) had pathological PR. Demographic characteristics, symptom pattern, and manometric findings did not differ in patients with normal or pathological PR. Patients with pathological PR had significantly higher DR and DGER. The multivariate analysis identified only pathological DR as an independent risk factor for the presence of pathological PR (odds ratio 4.515, 95% CI 2.48-8.23, p < 0.0001). Only 20 patients (6%) had pathological proximal reflux without pathological distal acid reflux., Conclusion: The findings of the present article do not support routine proximal esophageal pH monitoring as a clinical tool: PR does not differentiate patients with typical or atypical GERD manifestations and depends mainly on DR.
- Published
- 2004
- Full Text
- View/download PDF
44. Pulmonary alveolar proteinosis.
- Author
-
Collard B, Cool M, Hertveldt K, Claikens B, and Delanote G
- Subjects
- Adult, Biopsy, Bronchoalveolar Lavage, Bronchoscopy, Diagnosis, Differential, Dyspnea etiology, Humans, Lung diagnostic imaging, Lung pathology, Male, Pulmonary Alveolar Proteinosis pathology, Pulmonary Alveolar Proteinosis therapy, Pulmonary Alveolar Proteinosis diagnostic imaging, Tomography, X-Ray Computed
- Abstract
A 23-year-old man was admitted to the hospital because of dyspnea. Chest X-ray showed reticulo-nodular opacities. The crazy paving appearance on high-resolution CT was highly suggestive of pulmonary alveolar proteinosis. Histologic examination confirmed the diagnosis. Pulmonary alveolar proteinosis is a rare disease but an important diagnosis to make as treatment with pulmonary lavage is curative in a large proportion of patients.
- Published
- 2002
45. Phylogenetic footprinting reveals multiple regulatory elements involved in control of the meiotic recombination gene, REC102.
- Author
-
Jiao K, Nau JJ, Cool M, Gray WM, Fassler JS, and Malone RE
- Subjects
- Base Sequence, Binding Sites, Cloning, Molecular, DNA-Binding Proteins metabolism, DNA-Binding Proteins physiology, Meiosis genetics, Molecular Sequence Data, Promoter Regions, Genetic, Protein Binding, Recombinases, Recombination, Genetic, Repressor Proteins metabolism, Repressor Proteins physiology, Saccharomyces cerevisiae chemistry, Saccharomyces cerevisiae classification, Sequence Alignment, Fungal Proteins genetics, Gene Expression Regulation, Fungal, Genes, Fungal, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae Proteins, Telomere-Binding Proteins
- Abstract
REC102 is a meiosis-specific early exchange gene absolutely required for meiotic recombination in Saccharomyces cerevisiae. Sequence analysis of REC102 indicates that there are multiple potential regulatory elements in its promoter region, and a possible regulatory element in the coding region. This suggests that the regulation of REC102 may be complex and may include elements not yet reported in other meiotic genes. To identify potential cis-regulatory elements, phylogenetic footprinting analysis was used. REC102 homologues were cloned from other two Saccharomyces spp. and sequence comparison among the three species defined evolutionarily conserved elements. Deletion analysis demonstrated that the early meiotic gene regulatory element URS1 was necessary but not sufficient for proper regulation of REC102. Upstream elements, including the binding sites for Gcr1p, Yap1p, Rap1p and several novel conserved sequences, are also required for the normal regulation of REC102 as well as a Rap1p binding site located in the coding region. The data in this paper support the use of phylogenetic comparisions as a method for determining important sequences in complex promoters., (Copyright 2002 John Wiley & Sons, Ltd.)
- Published
- 2002
- Full Text
- View/download PDF
46. Development and maintenance of a B220- memory B cell compartment.
- Author
-
Driver DJ, McHeyzer-Williams LJ, Cool M, Stetson DB, and McHeyzer-Williams MG
- Subjects
- Amino Acid Sequence, Animals, B-Lymphocyte Subsets enzymology, B-Lymphocyte Subsets metabolism, Base Sequence, Bone Marrow Cells immunology, Cell Differentiation genetics, Cell Differentiation immunology, Cell Survival genetics, Cell Survival immunology, Epitopes, B-Lymphocyte immunology, Female, Germinal Center cytology, Germinal Center immunology, Haptens immunology, Immunoglobulin E biosynthesis, Immunoglobulin Heavy Chains genetics, Immunoglobulin lambda-Chains genetics, Immunophenotyping, Leukocyte Common Antigens biosynthesis, Macrophage-1 Antigen biosynthesis, Mice, Mice, Inbred C57BL, Molecular Sequence Data, Mutation, Nitrophenols immunology, Phenylacetates, Spleen cytology, Spleen immunology, B-Lymphocyte Subsets immunology, Immunologic Memory genetics, Leukocyte Common Antigens genetics
- Abstract
We have recently demonstrated that a novel somatically mutated B220(-) memory B cell subset rapidly dominates the secondary immune response to (4-hydroxy-3-nitrophenyl) acetyl (NP). Upon adoptive transfer with Ag, B220(+)NP(+) memory B cells produce large numbers of B220(-)NP(+) B cells that can rapidly differentiate into plasma cells. Therefore, it is not clear whether the novel B220(-) memory compartment is a consequence of secondary Ag challenge or whether it develops as a stable memory subset after initial Ag challenge. In this study, we demonstrate the gradual emergence of B220(-)NP(+) B cells in the spleen to maximal numbers 3 wk after initial Ag exposure. Like their B220(+) counterparts, the B220(-) B cells initially appear unmutated at days 5-7; however, the majority rapidly accumulate affinity increasing mutations by days 9-14 of the primary immune response. More extensive cell surface phenotype (GL7(-)BLA-1(-)CD24(-)CD43(+)) argues strongly against germinal center localization and direct analysis in situ places a cohort of B220(-)CD11b(+)NP(+) B cells in the red pulp of the spleen and not in the MZs. These data provide direct evidence for the development of B220(-) memory B cells as a unique cellular consequence of primary Ag exposure. The cellular dynamics and molecular attributes of these unique memory B cells suggest they are distinct cellular products of the germinal center reaction in the primary response and are maintained long-term in the spleen and bone marrow.
- Published
- 2001
- Full Text
- View/download PDF
47. Antigen-specific B cell memory: expression and replenishment of a novel b220(-) memory b cell compartment.
- Author
-
McHeyzer-Williams LJ, Cool M, and McHeyzer-Williams MG
- Subjects
- Animals, Antigens, CD immunology, B-Lymphocyte Subsets classification, B-Lymphocyte Subsets immunology, B-Lymphocytes classification, Base Sequence, Bone Marrow Cells immunology, CD79 Antigens, Cell Differentiation, Female, Haptens, Hemocyanins immunology, Immunoglobulin lambda-Chains immunology, Immunophenotyping, Leukocyte Common Antigens genetics, Macrophage-1 Antigen immunology, Membrane Glycoproteins genetics, Mice, Mice, Inbred C57BL, Molecular Sequence Data, Proteoglycans genetics, Spleen cytology, Spleen immunology, Syndecan-1, Syndecans, B-Lymphocytes immunology, Immunologic Memory immunology, Leukocyte Common Antigens immunology, Membrane Glycoproteins immunology, Proteoglycans immunology
- Abstract
The mechanisms that regulate B cell memory and the rapid recall response to antigen remain poorly defined. This study focuses on the rapid expression of B cell memory upon antigen recall in vivo, and the replenishment of quiescent B cell memory that follows. Based on expression of CD138 and B220, we reveal a unique and major subtype of antigen-specific memory B cells (B220(-)CD138(-)) that are distinct from antibody-secreting B cells (B220(+/)-CD138(+)) and B220(+)CD138(-) memory B cells. These nonsecreting somatically mutated B220(-) memory responders rapidly dominate the splenic response and comprise >95% of antigen-specific memory B cells that migrate to the bone marrow. By day 42 after recall, the predominant quiescent memory B cell population in the spleen (75-85%) and the bone marrow (>95%) expresses the B220(-) phenotype. Upon adoptive transfer, B220(-) memory B cells proliferate to a lesser degree but produce greater amounts of antibody than their B220(+) counterparts. The pattern of cellular differentiation after transfer indicates that B220(-) memory B cells act as stable self-replenishing intermediates that arise from B220(+) memory B cells and produce antibody-secreting cells on rechallenge with antigen. Cell surface phenotype and Ig isotype expression divide the B220(-) compartment into two main subsets with distinct patterns of integrin and coreceptor expression. Thus, we identify new cellular components of B cell memory and propose a model for long-term protective immunity that is regulated by a complex balance of committed memory B cells with subspecialized immune function.
- Published
- 2000
- Full Text
- View/download PDF
48. Elevated frequency of loss of heterozygosity in mammary tumors arising in mouse mammary tumor virus/neu transgenic mice.
- Author
-
Cool M and Jolicoeur P
- Subjects
- Acyltransferases, Alleles, Animals, Cadherins genetics, Crosses, Genetic, Female, Gene Deletion, Genes, p16, Male, Membrane Proteins genetics, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Chromosome Mapping, Genes, Tumor Suppressor, Genes, erbB-2, Loss of Heterozygosity, Mammary Neoplasms, Experimental genetics, Mammary Tumor Virus, Mouse genetics
- Abstract
Loss of heterozygosity (LOH) analysis was performed on 62 mammary tumors that were induced in (BALB/c x C57BL/6)F1 mouse mammary tumor virus/neu transgenic mice. Eighty-six simple sequence length polymorphism markers were used to cover all of the somatic chromosomes. Frequency of LOH was observed to be significant for chromosomes 4 (50%), 19 (32%), and 8 (21%). On chromosome 4, at least three distinct regions of allelic deletions could be identified: one proximal to 22 cM; the second close to the p16INK4a/p15INK4b locus, which is commonly deleted in various tumors; and the third one in the proximity of Mom1. The frequency of LOH on chromosome 19 was the same for the four markers used. Our data suggested the presence of two distinct LOH loci, one proximal to 47 cM and the other at the distal region. On chromosome 8, possibly two distinct LOH loci could be recognized, one around 52 cM and the other one at 67 cM or distal to it. These regions map close to E-cadherin (Cdh1) and M-cadherin (Cdh15) loci, respectively. Because LOH sites are thought to harbor tumor suppressor genes, this allelotype screening has allowed the mapping of putative tumor suppressor genes that may be implicated, in collaboration with the erbB-2/neu oncogene, in the development of mammary tumors in these transgenic mice.
- Published
- 1999
49. Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease.
- Author
-
Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, and Jolicoeur P
- Subjects
- Acquired Immunodeficiency Syndrome immunology, Acquired Immunodeficiency Syndrome pathology, Animals, Base Sequence, CD4 Antigens genetics, Chemokine CCL5 genetics, DNA Primers genetics, Disease Models, Animal, Female, Gene Expression, Genome, Viral, HIV-1 genetics, HIV-1 immunology, Humans, Immune System virology, Male, Mice, Mice, Inbred C3H, Mice, Inbred C57BL, Mice, Transgenic, Mosaicism, Phenotype, Acquired Immunodeficiency Syndrome etiology, HIV-1 pathogenicity
- Abstract
We have constructed transgenic (Tg) mice expressing the entire human immunodeficiency virus type 1 (HIV-1) coding sequences in cells targeted by HIV-1 infection in humans. These Tg mice developed a severe AIDS-like disease leading to early death (< 1 month). They developed muscle wasting, severe atrophy and fibrosis of lymphoid organs, tubulointerstitial nephritis, and lymphoid interstitial pneumonitis. In addition the expression of RANTES was increased in various tissues of these Tg mice relative to that in the normal controls. Disease appearance was correlated with the levels of transgene expression. The numerous pathologies observed in these mice are remarkably similar to those observed in human AIDS and, more specifically, in pediatric AIDS.
- Published
- 1998
- Full Text
- View/download PDF
50. Analysis of meiotic recombination pathways in the yeast Saccharomyces cerevisiae.
- Author
-
Mao-Draayer Y, Galbraith AM, Pittman DL, Cool M, and Malone RE
- Subjects
- Chromosomes, Fungal, Phenotype, Rad52 DNA Repair and Recombination Protein, Spores, Fungal physiology, DNA-Binding Proteins genetics, Fungal Proteins genetics, Gene Expression Regulation, Fungal, Recombination, Genetic, Saccharomyces cerevisiae genetics, Saccharomyces cerevisiae Proteins
- Abstract
In the yeast, Saccharomyces cerevisiae, several genes appear to act early in meiotic recombination. HOP1 and RED1 have been classified as such early genes. The data in this paper demonstrate that neither a red nor a hop1 mutation can rescue the inviable spores produced by a rad52 spo13 strain; this phenotype helps to distinguish these two genes from other early meiotic recombination genes such as SPO11, REC104, or MEI4. In contrast, either a red1 or a hop1 mutation can rescue a rad50S spo13 strain; this phenotype is similar to that conferred by mutations in the other early recombination genes (e.g., REC104). These two different results can be explained because the data presented here indicate that a rad50S mutation does not diminish meiotic intrachromosomal recombination, similar to the mutant phenotypes conferred by red1 or hop1. Of course, RED1 and HOP1 do act in the normal meiotic interchromosomal recombination pathway; they reduce interchromosomal recombination to approximately 10% of normal levels. We demonstrate that a mutation in a gene (REC104) required for initiation of exchange is completely epistatic to a mutation in RED1. Finally, mutations in either HOP1 or RED1 reduce the number of double-strand breaks observed at the HIS2 meiotic recombination hotspot.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.